# Mouse modeling of HPV infection

> **NIH NIH R01** · JOHNS HOPKINS UNIVERSITY · 2022 · $582,604

## Abstract

SUMMARY
Our overall goal is to create a laboratory mouse-based model of human papillomavirus (HPV) infection and
disease to support the development of novel HPV vaccines. Translational research requires animal models
that are robust representations of human pathology in which to test questions of clinical importance, and
provide reliable information for the development of novel interventions and patient benefit. HPV is the primary
etiologic agent of at least 5% of all cancers worldwide, mostly cervical and subsets of other anogential and
head and neck cancers and potentially also non-melanoma skin cancers. Unfortunately, there is no specific
antiviral therapy, but vaccine-based approaches are very promising. Many groups are bringing candidate
therapeutic HPV vaccines to the clinic, including our pNGLV4aCRTE6E7L2 DNA, but to date there has been
limited success in treating patients despite promising data with the vaccines in the current standard animal
models. This demonstrates the need for more predictive animal models. HPV does not complete its life cycle
and produce virions in mice or in cell culture monolayers and so HPV pseudovirions delivering a reporter
construct are often used. This system does not fully mimic the assembly and maturation of the viral capsid in
E4-expressing differentiating epithelium or provide a disease endpoint. A model that produces disease from
virus produced in a papilloma and expressing clinically-relevant HPV sequences is required. Therefore, we
propose to transform the utility of Mus musculus papillomavirus type 1 (MmuPV1) by incorporating key HPV
sequences and credential it for use as a model for testing novel therapeutic and protective HPV vaccines.
SPECIFIC AIM 1: To develop MmuPV1 viruses incorporating HPV sequences. Organ transplant recipients
(OTRs) and HIV+ patients exhibit more severe and progressive HPV disease, and dramatically higher rates of
HPV-associated malignancies. Non-melanoma skin cancers (NMSC) in immune-compromised patients are
associated with a plethora of βHPVs that were initially described in epidermodysplasia verruciformis (EDV)
patients. SPECIFIC AIM 2: To develop an MmuPV1-based mouse challenge model of human cohorts at
normal and high risk for the development of HPV-associated cancer. To validate these new murine
models of HPV infection and disease we propose to examine the efficacy of a licensed HPV vaccine and two of
our clinical grade experimental vaccines that will shortly enter early phase testing: RG1-VLP, a single virus-like
particle antigen intended to provide broad immunity against diverse HPV types, and the candidate therapeutic
DNA vaccine pNGLV4aCRTE6E7L2 administered via electroporation. SPECIFIC AIM 3: To compare the
efficacy of the Gardasil 9, pNGLV4aCRTE6E7L2 DNA and RG1-VLP vaccines against disease and viral
endpoints in murine models of healthy subjects and those at high risk for HPV-related cancer.

## Key facts

- **NIH application ID:** 10304917
- **Project number:** 5R01CA233486-04
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Chien-Fu Hung
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $582,604
- **Award type:** 5
- **Project period:** 2018-12-01 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10304917

## Citation

> US National Institutes of Health, RePORTER application 10304917, Mouse modeling of HPV infection (5R01CA233486-04). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10304917. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*